Who is Baysient?
Baysient creates cloud-based software to facilitate individualized dosing of anti-inflammatory MAbs to improve outcomes in patients with inflammatory diseases like IBD. Baysient’s software utilizes a pioneering Compuceutical approach with Bayesian models, routine lab results and demographic information to allow physicians to individualize dosing to a specific target trough level.
Why Baysient?
How Does It Work?
Schedule a Demo
Interested in how iDose can improve your patient outcomes?
Diane R. Mould, PhD
Dr. Diane R. Mould, Chief Scientific Officer (CSO) of Baysient, discusses individual variability in infliximab excretion and elimination. The variations seen in the individual pharmacokinetics of biologics highlight the need for more prospective data to further support effective personalized dosing. By focusing on important, modifiable factors for regulating drug levels, we can improve the efficacy of inflammatory disease treatments in clinical settings.
Latest Blog Post
Real-world Evidence: How iDose Optimized Infliximab Therapy in Indian IBD Patients
When it comes to managing inflammatory bowel disease (IBD) with infliximab (IFX), the traditional approach of standard dosing leaves many patients behind. A groundbreaking 2020 study from Mumbai's P.D. Hinduja Hospital demonstrates how Baysient's iDose software is changing that reality by delivering better clinical outcomes…
